Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12933-020-01089-2 http://scihub22266oqcxt.onion/10.1186/s12933-020-01089-2 32690029!7370631!32690029     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32690029&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cardiovasc+Diabetol 2020 ; 19 (1): 114 Nephropedia Template TP {{tp|p=32690029|t=2020. Issues for the management of people with diabetes and COVID-19 in ICU |pdf=|usr=}}{{32690029}} gab.com Text Issues for the management of people with diabetes and COVID-19 in ICU JO: Cardiovasc Diabetol http://www.kidney.de/pget.php?&tw=1&pmid=32690029 #FOAvip In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. An optimal glycemic control, avoiding acute hyperglycemia, hypoglycemia and glycemic variability may significantly improve the outcome. In this case, intravenous insulin infusion with continuous glucose monitoring should be the choice. No evidence suggests stopping angiotensin-converting-enzyme inhibitors, angiotensin-renin-blockers or statins, even it has been suggested that they may increase the expression of Angiotensin-Converting-Enzyme-2 (ACE2) receptor, which is used by "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to penetrate into the cells. A real issue is the usefulness of several biomarkers, which have been suggested to be measured during the COVID-19. N-Terminal-pro-Brain Natriuretic-Peptide, D-dimer and hs-Troponin are often increased in diabetes. Their meaning in the case of diabetes and COVID-19 should be therefore very carefully evaluated. Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act. Twit Text FOAVip Issues for the management of people with diabetes and COVID-19 in ICU ????Cardiovasc Diabetol http://www.kidney.de/pget.php?&tw=1&pmid=32690029 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32690029 #FOAvip English Wikipedia <ref>{{Cite pmid|32690029}}</ref> Issues for the management of people with diabetes and COVID-19 in ICU #MMPMID32690029 Ceriello A; Standl E; Catrinoiu D; Itzhak B; Lalic NM; Rahelic D; Schnell O; Skrha J; Valensi P Cardiovasc Diabetol 2020[Jul]; 19 (1): 114 PMID32690029show ga In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. An optimal glycemic control, avoiding acute hyperglycemia, hypoglycemia and glycemic variability may significantly improve the outcome. In this case, intravenous insulin infusion with continuous glucose monitoring should be the choice. No evidence suggests stopping angiotensin-converting-enzyme inhibitors, angiotensin-renin-blockers or statins, even it has been suggested that they may increase the expression of Angiotensin-Converting-Enzyme-2 (ACE2) receptor, which is used by "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to penetrate into the cells. A real issue is the usefulness of several biomarkers, which have been suggested to be measured during the COVID-19. N-Terminal-pro-Brain Natriuretic-Peptide, D-dimer and hs-Troponin are often increased in diabetes. Their meaning in the case of diabetes and COVID-19 should be therefore very carefully evaluated. Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act. |*Intensive Care Units[MESH] |Antihypertensive Agents/therapeutic use[MESH] |Betacoronavirus/*pathogenicity[MESH] |Biomarkers/blood[MESH] |Blood Glucose/*drug effects/metabolism[MESH] |COVID-19[MESH] |Coronavirus Infections/diagnosis/mortality/*therapy/virology[MESH] |Diabetes Mellitus/blood/diagnosis/*drug therapy/mortality[MESH] |Dyslipidemias/drug therapy/mortality[MESH] |Host-Pathogen Interactions[MESH] |Humans[MESH] |Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use[MESH] |Hypertension/drug therapy/mortality[MESH] |Hypoglycemic Agents/adverse effects/*therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/mortality/*therapy/virology[MESH] |Risk Assessment[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH]Issues for the management of people with diabetes and COVID-19 in ICU (epmc).pdf DeepDyve Pubget Overpricing